TEVA-PHARMACEUTICAL
Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. Initial launches are planned in Portugal, Switzerland, Spain and the UK.
Introducing Seffalair Spiromax and BroPair Spiromax
The launch of Seffalair Spiromax and BroPair Spiromax further extends Teva’s respiratory portfolio, and provides healthcare professionals another option in treating people living with asthma. Since the launch of DuoResp® Spiromax® (budesonide/formoterol), the Spiromax® inhaler has been well received by healthcare professionals and patients.1,2
Inhaler technique and treatment adherence are key factors in improving outcomes for asthma patients, of which there are an estimated 28 million in the EU.3,4
"We are excited about the European approval of Seffalair Spiromax and BroPair Spiromax, as an important goal of our respiratory franchise is to bring new treatment options to healthcare professionals who support people living with long-term conditions such as asthma,” says Paul Blonk, Head of Teva Respiratory Europe. “We want to empower patients to effectively manage their condition through the medicines we provide, whilst also offering cost-effective treatments to healthcare systems.”
About Seffalair Spiromax and BroPair Spiromax (salmeterol xinafoate / fluticasone propionate)
Seffalair Spiromax and BroPair Spiromax are indicated as a regular treatment for asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonists.
About Teva Respiratory
Teva Respiratory develops and delivers high-quality treatment options for respiratory conditions, including asthma, COPD and cystic fibrosis. The Teva Respiratory portfolio is centred on optimizing respiratory treatment for patients and healthcare providers through the development of novel delivery systems and therapies that help address unmet needs. Teva’s respiratory pipeline and clinical trial program are based on drug molecules delivered in proprietary dry powder formulations and breath-actuated device technologies, as well as a targeted biologic treatment for severe asthma. Through research and clinical development, Teva Respiratory continually works to expand, strengthen and build upon its treatment portfolio to positively impact the lives of the millions of patients living with respiratory disease.
About Teva
Teva Pharmaceuticals Europe makes life-saving and life-improving medicines more accessible for millions of people around the world. We focus on treatments for migraine, conditions of the central nervous system including pain, as well as respiratory conditions like asthma and COPD and have a portfolio in oncology. Our mission is to be a global leader in generics and biopharmaceuticals improving the lives of patients around the globe.
Building on more than a century-old legacy we have an established presence in generics, specialty, over-the-counter (OTC) and active pharmaceutical ingredients (API). With a fully integrated R&D function, strong operational base and global infrastructure and scale we invest millions of dollars to help our scientists find the next breakthrough.
We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 40,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com .
References
- van der Palen et al. Poster presented at the ERS International Congress, Paris, France, September 2018 (PA1020).
- Roche N, et al. J Asthma, 2021; DOI: 10.1080/02770903.2021.1875482
- GBD. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. 392 (10159):1789-858.
- Eurostat. First population estimates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors22.10.2025 22:15:00 CEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Brett Icahn and Richard Mulligan, Ph.D., to its board of directors, effective Oct. 20. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022380951/en/ Brett Icahn (Photo: IFF) These appointments follow the company’s previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Icahn serves as the Icahn designee to the IFF board, replacing Vincent Intrieri, and Mulligan joined as the mutually agreed independent director, replacing Margarita Paláu-Hernández. Intrieri and Paláu-Hernández stepped down from the board on Oct. 20. Icahn has been named to the Board’s Audit Committee and Transaction Committee, and Mulligan has been named to the Board’s Innovation Committee. “We are very pleased to welcome Brett and Richard to the IFF board,” said Kevin O’Byrne, chair of the IFF boa
OpenAI, Oracle and Vantage Data Centers Announce Stargate Data Center Site in Wisconsin22.10.2025 22:05:00 CEST | Press release
Vantage’s $15B+ investment in Port Washington represents the future of sustainable digital infrastructure with zero-emission energy resources, water-positive operations and billions in regional economic growth OpenAI, Oracle and Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced plans to develop a data center campus outside Milwaukee in Port Washington, Wisconsin. The new campus is part of OpenAI and Oracle’s previously announced partnership to invest up to 4.5 gigawatts of additional Stargate capacity and is the Midwest site that was recently announced as part of OpenAI’s Stargate expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022873578/en/ Vantage Data Centers’ $15B+ campus in Port Washington, Wisconsin represents the future of sustainable digital infrastructure. The campus will feature four cutting-edge data centers providing close to a gigawatt of AI capacity
Pure Lithium Opens New Chicago Headquarters, Advancing Commercialization of Its Lithium Metal Battery22.10.2025 19:24:00 CEST | Press release
Pure Lithium Corp., a disruptive vertically integrated lithium metal battery technology company, officially opened its new headquarters in Chicago’s Fulton Market district with a ribbon cutting ceremony Tuesday attended by community and business leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022239586/en/ From left: Ken Hoffman, Pure Lithium Special Advisor; Dr. Yuan Gao, Member of Pure Lithium Scientific Advisory Board; Derek Willis, Vice President of Commercial Development at Oxy Low Carbon Ventures and Pure Lithium Board Director; Miss Illinois Nitsaniyah Fitch; Chicago Mayor Brandon Johnson; Pure Lithium Founder, Chairman & CEO Emilie Bodoin; Illinois State Senator Lakesia Collins; Former Massachusetts Governor & Pure Lithium Board Director William F. Weld; Lisa Clemmons-Stott, Senior Economic Advisor, Director’s Office, Illinois Department of Commerce and Economic Opportunity The opening marks a milestone in
Doha Debates Launches New Debate Season with Al Jazeera22.10.2025 19:07:00 CEST | Press release
The new season brings global voices together for truth-seeking discussions Qatar Foundation’s Doha Debates launched a new season of its flagship program, Doha Debates, on October 21, co-produced with Al Jazeera Digital. The upcoming season features high-profile guests, bold global themes and a renewed focus on open, truth-seeking dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022828303/en/ Qatar Foundation’s Doha Debates launches new debate season, bringing global voices together for truth-seeking discussions. (photo: AETOSWire) Airing weekly on Tuesdays through December 9, the eight-episode season explores three overarching themes—freedom, grand narratives and family. Each episode features leading thinkers and young changemakers engaging in timely conversations on the issues shaping humanity, ranging from meritocracy to social media; from love to architecture; from ancient traditions to the future of work. The
Picsart, Gen Z’s Preferred Digital Content Creation Platform, Takes LinkedIn Creators to Dracula’s Castle for “Why Your Marketing Sucks” Halloween Campaign22.10.2025 18:23:00 CEST | Press release
Picsart, the world’s leading digital creation platform, has announced the release of its new Halloween campaign and ebook, Why Your Marketing Sucks: a highly visual, tongue-in-cheek guide to the scariest mistakes marketers make and how to avoid them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022722043/en/ Why Your Marketing Sucks Ebook by Picsart The campaign, running from October 15 through October 31, combines horror-themed storytelling with practical marketing advice and expertise. Its centerpiece, the Why Your Marketing Sucks ebook, was co-created by Picsart and five top LinkedIn marketing influencers during an exclusive brand trip to Transylvania to visit Bran Castle — thought to be the home of Count Dracula himself. Picsart’s COO and Co-Founder, Mikayel Vardanyan, said “Gen Z represents more than 25% of today’s workforce. Picsart has been supporting this demographic for 15 years — more than half of our users ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom